ACT-PRESTO (active clarity technique–pressure related efficient and stable transfer of macromolecules into organs) enables rapid, efficient, but inexpensive tissue clearing and rapid antibody penetration into cleared tissues by passive diffusion or pressure-assisted delivery. Using this method, a wide range of tissues can be cleared, immunolabeled by multiple antibodies, and volume-imaged.
The identification and exploration of the detailed organization of organs or of the whole body at the cellular level are fundamental challenges in biology. Transitional methods require a substantial amount of time and effort to obtain a 3D image and including sectioning the intact tissue, immunolabeling, and imaging serially-sectioned tissue, which produces a loss of information at each step of the process. In recently developed approaches for high-resolution imaging within intact tissue, molecular characterization has been restricted to the labeling of proteins. However, currently available protocols for organ clearing require a considerably long process time, making it difficult to implement tissue clearing techniques in the lab. We recently established a rapid and highly-reproducible protocol termed ACT-PRESTO (active clarity technique–pressure related efficient and stable transfer of macromolecules into organs), which allows for tissue clearance within several hours. Moreover, ACT-PRESTO enables rapid immunolabeling with conventional methods and accelerates antibody penetration into the deep layer of densely-formed, thick specimens by applying pressure or convection flow. We describe how to prepare tissues, how to clear by lipid removal using electrophoresis, and how to immuno-stain by a pressure-assisted delivery. The rapidity and consistency of the protocol will expedite the performance of 3D histological research and volume-based diagnoses.
One of the challenges in neuroscience is the visualization of neuronal circuit wiring and individual cells within intact brain tissue. Until recently, demonstrating the connections between neurons in this way required 1) serial sectioning of tissues; 2) molecular labeling of specific targets, such as axons or proteins; and 3) visualization by 3D reconstruction of the whole brain via computational registering or alignment of 2D serial images1. These steps are laborious, require a great deal of time, and are liable to lose information during sectioning and labeling, making neuronal network mapping exceedingly difficult. However, many methods that allow for the visualization of intact tissue without sectioning have been developed. Biological tissues can be made optically transparent by tissue-clearing techniques2-10. One of the major methods is to reduce refractive index differences between the intact tissue and the immersion solution in order to reduce light scattering in the intact tissue, thus rendering the tissue transparent and enabling the observation of deep structures. Some types of immersion solutions have hydrophobic properties, which result in fast fluorescent quenching during the dehydration procedure. Therefore, those methods are not compatible with fluorescent imaging over a long period of time11,12. Instead of hydrophobic reagents, other methods use hydrophilic reagents for tissue clearing, such as SeeDB4 and Scale6, which maintain the structural information and fluorescence of the biological tissue4,6,8. However, macromolecules, including antibodies, cannot reach the core of intact tissue by diffusion alone. Therefore, the pre-labeling of target molecules in deep areas of densely-packed tissues is technically challenging.
In a recently-developed tissue-clearing method, CLARITY3, a hydrogel-embedded biological tissue is formed with acrylamide, and lipids are removed by electrophoresis under sodium dodecyl sulfate (SDS)-containing solution. The sample is then immersed in a solution with a matching reflective index to reduce light scattering3. The lipid removal system was later modified in advanced CLARITY13 and PACT (passive clarity technique)10. After polymerization, acrylamide chains crosslink with proteins, forming hydrogel-tissue. Lipid components cannot crosslink with acrylamide; thus, lipids can be eliminated by electrophoresis under the SDS-containing buffer. Through the active elimination of lipids, brain tissue markedly increases in transparency9. However, these methods do not address the impossibility of deep-labeling by free diffusion. To overcome this limitation, techniques for the active transport of reagents into the deepest parts of thick tissues are required.
Although CLARITY allows tissue clearing and deep-tissue visualization, it is not an easy or fast procedure. It can take several weeks to clear a whole mouse brain7,14. Rapid clearing of tissues is essential for the application of such methods to basic or clinical laboratory settings for life science research or volume diagnosis. The current protocol provides a simplified process for biological tissue clearance and subsequent protein detection by pressure-assisted delivery immuno-staining. It is suitable for high-resolution volume imaging of large filed and 3D data processing systems through combination with imaging methods.
Animal experiments must conform to all relevant governmental and institutional regulations.
1. Preparation of Reagents
2. Sample Preparation & Fixation
3. Hydrogel Monomer Infusion and Polymerization
4. Electrophoretic Tissue Clearing (ETC)
5. Immunolabeling of ACT-processed Tissues
6. Immunolabeling of Dense Tissues (PRESTO)
7. Imaging
ACT-tissue Clearing
One important factor affecting tissue clearing is tissue fixation. PFA fixation and acrylamide infusion are separate steps in this protocol. After the tissue-hydrogel polymerization step, the free A4P0 solution is not polymerized, although tissue-infused hydrogels are cross-linked with endogenous macromolecules. Therefore, no gel should form outside of the tissues (Figure 2A). The ACT procedure results in less cross-linking between proteins and acrylamide compared to the CLARITY protocol. Accordingly, the tissue-hydrogel sample is more porous. This feature enables the fast extraction of lipids and the diffusion of macromolecules. Sections of mouse brain 1- to 2-mm thick were sufficiently cleared within 1 – 2 h (Figure 2B), and 5 – 6 h of ETC was sufficient for clearance of whole mouse brains (Figure 2C). Hydrogel-mediated tissue clearing induced the expansion of the tissue after the ETC step, but the tissue returned to its original size in reflective index-matched solution. The tissue-hydrogel sample formed in the ACT procedure is highly porous, and thus, small compounds and macromolecules could penetrate efficiently and diffuse easily (Figure 3). After a 2-h incubation of 1-mm brain slices with tyrosine hydroxylase (TH) and collagen type IV antibody, a subsequent 2-h incubation with a secondary antibody was sufficient to label dopaminergic neurons at a 500-µm depth (Figure 3).
PRESTO-tissue Immunolabeling
Dense organs generally have high concentrations of ECM fibers, which affects the penetration of antibodies into the tissues. Thus, antibodies penetrated to a depth of only 20-30 µm in dense tissues, such as kidney tissue, after 12 h of incubation. To overcome this limitation, we designed active macromolecule penetration methods that enable the delivery of reagents into deep tissues, namely PRESTO (pressure related efficient and stable transfer of macromolecules into the organs) (Figure 4). Compared to the static incubation of ACT-processed kidney tissue with antibody solutions, the application of centrifugal forces (600 x g) with a table-top centrifuge (centrifugal PRESTO, c-PRESTO) greatly improved antibody delivery into deep tissue (Figure 5). When we applied the c-PRESTO procedure to dense tissues, 3 h of incubation was sufficient to label 250- to 300-µm deep structures. To improve the tissue distortion without significant tissue damage, we also designed a machine that provides convection flow with a syringe pump (syringe PRESTO, s-PRESTO). This process similarly improved antibody penetration compared to passive diffusion (Figure 5).
Figure 1. Preparation of the s-PRESTO apparatus. A. A syringe (30 mL) and three-way stopcock. B. The three-way stopcock connected and glued to the syringe. C. The syringe containing the sample and antibody solution, and the syringe placed on the syringe pump. D. The syringe pump and working condition setup. E. The pump infuses a solution containing the labeling reagents into the specimen. When the designated volume is reached, the pumping direction changes and withdraws the solution after a designated period of time. Please click here to view a larger version of this figure.
Figure 2. ACT tissue clearing of mouse brain. A. After polymerization, free A4P0 solutions are not polymerized; tissue-infused hydrogels are gelated by cross-linking with endogenous macromolecules. B. 1- to 2-mm thick brain slices were cleared for 1 – 2 h, and the extent of expansion and size recovery in reflective index (RI)-matching solution were recorded. C. The thickness of the whole mouse brain is about 0.8 cm, and 5 – 6 h of ETC was sufficient to completely clear the brain. After 3 h of ETC, there was a significant amount of non-cleared tissue. By 6 h of ETC, however, clearing of the entire brain had occurred. The color of tissues after ACT in the ETC buffer is white or opaque. By RI adjustment, tissues become transparent. Please click here to view a larger version of this figure.
Figure 3. Immunolabeling with ACT-cleared mouse brain tissue. Images of ACT-processed 1-mm mouse brain slices showing mouse brain cortex stained with an antibody to collagen type IV and part of the midbrain stained with an antibody to tyrosine hydroxylase (TH). Scale bar, 100 µm. Please click here to view a larger version of this figure.
Figure 4. PRESTO immunolabeling methods. Antibodies cannot penetrate into dense tissues by diffusion. PRESTO immunolabeling methods were designed to actively infuse macromolecules and to deliver reagents into dense tissues. The application of centrifugal forces using a standard table-top centrifuge (centrifugal PRESTO, c-PRESTO) markedly facilitated the delivery of antibodies. Appling convection flow with a syringe pump (syringe PRESTO, s-PRESTO) improved antibody penetration. Please click here to view a larger version of this figure.
Figure 5. PRESTO immunolabeling of ACT-cleared dense tissue. For c-PRESTO, tissues were centrifuged at 600 x g for 3 h using a standard table-top centrifuge in order to accelerate the penetration of primary and secondary antibodies. For s-PRESTO, a syringe pump was used to deliver the antibodies. Mouse organs, such as the kidneys and liver, were labeled with collagen type IV. Compared to conventional methods, 3 h of c- or s-PRESTO markedly enhances the labeling depth. In the kidney and liver, the depth of the Z-axis reaches 300 – 350 µm or deeper in PRESTO samples (right), while control samples are labeled at a depth of only 40 – 50 µm (left). A 3D reconstructed image was obtained with a confocal microscope. Scale bar, 100 µm. Please click here to view a larger version of this figure.
Poor fixation or hydrogel immersion into tissues can cause the loss of proteins and the distortion of tissue during the tissue clearing process. The whole adult mouse brain should be incubated in 4% paraformaldehyde overnight, followed by immersion in a minimum volume of 20 mL of hydrogel monomer solution for 12 – 18 h with gentle shaking. For large tissues, including human tissue such as brain slices and spinal cord, extended soaking time in the hydrogel monomer solution is required. The ACT protocol is easily applicable to the clearing of fixed tissues because the tissue fixation and polymer infusion steps are separated. After tissue clearing, human tissues were well-stained with several antibodies. Note that the ACT clearing technique is not compatible with alcohol fixatives, such as ethanol and methanol.
The tissue-hydrogel polymerization step is also critical to produce good-quality tissue following the clearing process. Because oxygen inhibits the polymerization of acrylamide, it should be removed by degassing the tissue-containing solution under a nitrogen gas infusion system. Alternatively, de-oxygenation can be executed using a vacuum chamber with a heat block for 23 h.
The clearing rate is dependent upon numerous factors, including the organ size, the contents of lipids or ECM fibrous proteins, the condition of fixation, etc. Most adult mouse tissues can be cleared by ETC overnight. However, there is a risk of unnecessary over-clearing and tissue swelling; thus, the differences in clearing time are of important consideration. Tissue-clearing conditions should be empirically determined. Importantly, the contents of the ECM may affect the appearance of the cleared tissue. The color of the tissues remains white or opaque, even after the ACT in ETC buffer, because ACT does not clear dense protein fibers. However, when these organs were immersed in RI matching solution, they became transparent.
The rate of tissue swelling appears to be dependent upon the ECM contents of the tissues, and soft organs, such as the brain, exhibit a greater swelling ratio than dense organs. Because increased tissue swelling will help the tissue-clearing procedure, ACT routinely utilizes distilled water-based buffer in most cases. In some cases, when tissue swelling or transient deformity is not desirable, such as in embryos, buffer containing 0.1x PBS can be applied for high-resolution imaging. It should be also noted that higher salt concentrations in the buffer could cause the shrinkage of tissues.
The ACT method can clarify whole organs and even the whole body of a mouse14. However, deep-tissue imaging of transparent tissue requires special microscopes and objectives. Thus, brain tissue 1- to 2-mm thick is most effective for imaging with a conventional confocal microscope. In our hands, removal of the labeled antibodies from ACT-processed tissues is antibody-dependent, and rounds of different antibody labeling are not recommended. Several antibodies, such as TH and GFAP, worked especially well for whole-brain immunolabeling14. On the other hand, some antibodies, such as Tuj1 or Map2, often labeled only the surface of the tissues. This might be improved by other methods, such as SWITCH15. Another potential limitation is that it might be difficult to preserve fine protein structures in ACT-processed tissue because of the tissue swelling and shrinkage during the tissue-clearing step.
The PRESTO technique is applicable to a wide variety of tissue-labeling techniques. For example, in tissue-transparent methods using pre-labeled tissue, such as SeeDB4 and iDISCO7, immunolabeling of dense tissue requires incubation periods longer than several days to weeks. However, PRESTO can shorten the incubation time to several hours, enabling the completion of the entire process within a day with 1-mm thick dense tissue. PRESTO can enhance the efficacy of deep-labeling thick, dense tissues, or even un-cleared thick tissues. Because PRESTO uses a table-top centrifuge or syringe pump and does not require any special equipment, it is relatively easy to implement this technique with routine lab procedures.
The authors have nothing to disclose.
This research was supported by the Brain Research Program through the National Research Foundation (NRF) funded by the Korean Ministry of Science, ICT, and Future Planning (NRF-2015M3C7A1028790).
4% Paraformaldehyde | Lugen SCI | LGB-1175-4B | sample fixation |
Acrylamide | Affymetrix | 75820 | Hydrogel monomer solution |
2,2’-Azobis[2-(2-imidazolin-2-yl) propane] dihydrochloride | Wako Pure Chemical Industries | VA-044 | Hydrogel monomer solution |
Boric acid | Affymetrix | 76324 | ETC buffer |
Sodium Dodecyl Sulfate (SDS) | Affymetrix | 18220 | ETC buffer |
Sodium hydroxide pellets | Junsei chemical | 1310-73-2 | ETC buffer |
Bovine Serum Albumin (BSA) | Santa Cruz Biotechnology | sc-2323A | Immunolabeling |
Triton X-100 | Sigma-Aldrich | T8787 | Immunolabeling |
Sodium azide | Sigma-Aldrich | S2002 | Immunolabeling |
Collagen type Ⅳ | Abcam | AB6586 | Antibody/immunolabeling |
Tyrosine hydroxylase (TH) | Millipore | AB152 | Antibody/immunolabeling |
Alexa Fluor Cy3 Donkey anti-Rabbit IgG (H+L) | Jackson ImmunoResearch | 711-165-152 | Secondary antibody/ immunolabeling |
Alexa Fluor 488 Donkey anti-Rabbit IgG (H+L) | Life Technologies – Molecular Probes | A21206 | Secondary antibody/ immunolabeling |
Confocal dish | SPL lifesciences | 101350 | Imaging |
Confocal microscope | Leica | SP8 | Imaging |
Sucrose | Junsei chemical | 31365-0301 | CUBIC-mount solution |
Urea | Affymetrix | 23036 | CUBIC-mount solution |
N,N,N’,N’-tetrakis(2-hydroxypropyl)ethylenediamine | Sigma-Aldrich | 122262 | CUBIC-mount solution |
ECT chamber | Logos Biosystems, Inc. | C10101 | ETC system |
ECT chamber controller | Logos Biosystems, Inc. | C10201 | ETC system |
Temperature probe | Logos Biosystems, Inc. | C12101 | ETC system |
Peristatic pump | Baoding longer precision pump Co., Ltd | YZ1515X | ETC system |
Buffer reservoir | Logos Biosystems, Inc. | C10401 | ETC system |
Tissue container | Logos Biosystems, Inc. | C12001 | ETC system |
Container holder for 1 tissue container | Logos Biosystems, Inc. | C12002 | ETC system |
Mouse brain slice holder | Logos Biosystems, Inc. | C12004 | ETC system |
Whole rat brain holder | Logos Biosystems, Inc. | C12007 | ETC system |
Peristaltic pump tubing | Logos Biosystems, Inc. | C12104 | ETC system |
Tabletop-centrifuge | Hanil science industrial Co., Ltd | MICRO 12 | c-PRESTO |
Syringe pump | Baoding longer precision pump Co., Ltd | LSP02-1B | s-PRESTO |
Syringe (20 ml) | Korea vaccine Co., Ltd. | KV-S20 | s-PRESTO |
3-way stopcock | Hyupsung medical Co.,Ltd. | HS-T-01N | s-PRESTO |